InspireMD adds Cohen to key board committees

InspireMD, Inc. updated its prior disclosure about board member Raymond W. Cohen.

Rhea-AI Filing Summary

InspireMD, Inc. updated its prior disclosure about board member Raymond W. Cohen. The company’s board has now appointed Mr. Cohen to serve on both the Audit Committee and the Compensation Committee, in addition to his existing role as a Class 3 director with a term running through the 2026 annual meeting.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did InspireMD (NSPR) disclose regarding Raymond W. Cohen?

InspireMD reported that Raymond W. Cohen, already a Class 3 director, has now been appointed to the company’s Audit Committee and Compensation Committee. This clarifies his full board responsibilities beyond his previously disclosed director role.

What board class does Raymond W. Cohen serve in at InspireMD (NSPR)?

Raymond W. Cohen serves as a Class 3 director on InspireMD’s board. His term as a Class 3 director is scheduled to expire at the company’s 2026 annual meeting of stockholders, aligning his service period with that director class cycle.

Which InspireMD (NSPR) board committees now include Raymond W. Cohen?

Raymond W. Cohen has been appointed to InspireMD’s Audit Committee and Compensation Committee. These committees oversee financial reporting and executive pay matters, expanding his responsibilities beyond his general duties as a Class 3 director.

Does this InspireMD (NSPR) update change Raymond W. Cohen’s director term?

The update does not change Raymond W. Cohen’s director term; he remains a Class 3 director with a term expiring at the 2026 annual meeting. It only adds clarity about his roles on the Audit and Compensation Committees.

Why did InspireMD (NSPR) issue an amendment related to Raymond W. Cohen?

InspireMD issued the amendment to specify the board committees to which Raymond W. Cohen was appointed. The earlier disclosure did not include committee assignments, and this update provides the required detail on his Audit and Compensation Committee roles.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/08/2025 - 04:05 PM EDT Learn about SEC filing dates

true 0001433607 0001433607 2025-07-30 2025-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 7, 2025 (July 30, 2025)

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35731		26-2123838
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6303 Waterford District Drive, Suite 215 Miami, Florida		33126
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 776-6804

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NSPR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Election of Directors

On July 31, 2025, InspireMD, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) with the Securities and Exchange Commission (“SEC”) announcing that its board of directors (the “Board”) appointed Mr. Raymond W. Cohen to serve as a Class 3 director on the Board, with a term expiring at the Company’s 2026 annual meeting of stockholders. At the time the Original Form 8-K was filed, the Board had not made a determination regarding any Board committee assignments for Mr. Cohen.

On September 7, 2025, the Board appointed Mr. Cohen to serve as a member of the Audit Committee and the Compensation Committee of the Board.

This Amendment No. 1 to the Original Form 8-K is being filed solely to report the Board committees to which Mr. Cohen has been appointed, as required by the SEC. Except as set forth herein, the Original Form 8-K remains unchanged in all respects.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		INSPIREMD, INC.
Date:	September 8, 2025	By:	/s/ Marvin Slosman
		Name:	Marvin Slosman
		Title:	Chief Executive Officer